Biotechnology

AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates

AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimatesAbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates

Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The…

Bristol-Myers Squibb swings to profit in Q1 2025; revenue drops

Bristol-Myers Squibb swings to profit in Q1 2025; revenue dropsBristol-Myers Squibb swings to profit in Q1 2025; revenue drops

Bristol Myers Squibb (NYSE: BMY) reported net profit for the first quarter of 2025, compared to a loss last year.…

MRK Earnings: Merck & Co. Q1 adj. profit rises, beats estimates

MRK Earnings: Merck & Co. Q1 adj. profit rises, beats estimatesMRK Earnings: Merck & Co. Q1 adj. profit rises, beats estimates

Merck & Co. Inc. (NYSE: MRK) Thursday reported an increase in adjusted earnings for the first quarter of 2025, while…

Earnings: Intuitive Surgical (ISRG) reports higher revenue and profit for Q1 2025

Earnings: Intuitive Surgical (ISRG) reports higher revenue and profit for Q1 2025Earnings: Intuitive Surgical (ISRG) reports higher revenue and profit for Q1 2025

Healthcare technology company Intuitive Surgical Inc. (NASDAQ: ISRG) Wednesday reported a sharp increase in revenue and adjusted earnings for the…

Abbott Laboratories (ABT) Q1 2025 Earnings: Key financials and quarterly highlights

Abbott Laboratories (ABT) Q1 2025 Earnings: Key financials and quarterly highlightsAbbott Laboratories (ABT) Q1 2025 Earnings: Key financials and quarterly highlights

Abbott Laboratories (NYSE: ABT) reported its first quarter 2025 earnings results today. Total sales increased 4% year-over-year to $10.35 billion.…

OS Therapies is actively advancing its osteosarcoma immunotherapy: CEO Paul Romness

OS Therapies is actively advancing its osteosarcoma immunotherapy: CEO Paul RomnessOS Therapies is actively advancing its osteosarcoma immunotherapy: CEO Paul Romness

OS Therapies (NYSE: OSTX) is a cancer immunotherapy company engaged in the development of new treatments for osteosarcoma and other…

Illumina (ILMN) expects adjusted EPS of approximately $4.50 for FY25

Illumina (ILMN) expects adjusted EPS of approximately $4.50 for FY25Illumina (ILMN) expects adjusted EPS of approximately $4.50 for FY25

Biotechnology company Illumina, Inc. (NASDAQ: ILMN) has issued fresh earnings guidance for fiscal 2025, to reflect tariff-related challenges to export.…

Earnings Summary: Moderna slips to loss in Q4; revenue down 66%

Earnings Summary: Moderna slips to loss in Q4; revenue down 66%Earnings Summary: Moderna slips to loss in Q4; revenue down 66%

Biotechnology company Moderna, Inc. (NASDAQ: MRNA) has reported a net loss for the fourth quarter of 2024, compared to a…

Key metrics from Biogen’s (BIIB) Q4 2024 earnings results

Key metrics from Biogen’s (BIIB) Q4 2024 earnings resultsKey metrics from Biogen’s (BIIB) Q4 2024 earnings results

Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter 2024 earnings results today. Total revenue increased 3% year-over-year to $2.5 billion.…

Highlights of Bristol-Myers Squibb’s Q4 2024 earnings report

Highlights of Bristol-Myers Squibb’s Q4 2024 earnings reportHighlights of Bristol-Myers Squibb’s Q4 2024 earnings report

Biotechnology company Bristol Myers Squibb (NYSE: BMY) reported lower profit for the fourth quarter of 2024, despite an increase in…

LLY Earnings: Eli Lilly Q4 2024 profit more than doubles; revenue up 45%

Eli Lilly and Company (NYSE: LLY) Thursday reported a sharp increase in its fourth-quarter revenues. The pharmaceutical company's adjusted earnings…

MRK Earnings: Merck Q4 2024 adj. profit jumps on strong sales growth

Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the fourth quarter of…

AbbVie Q4 2024 adjusted earnings decline despite 6% revenue growth

Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced fourth-quarter 2024 financial results, reporting a double-digit dip in adjusted earnings and an…

Earnings Summary: DexCom reports preliminary Q4 2024 results

DexCom, Inc. (NASDAQ: DXCM) has announced preliminary financial results for the fourth quarter of 2024, reporting an 8% increase in…

NeOnc Technologies plans to go public through direct listing

NeOnc Technologies Holdings Inc., a privately held clinical-stage biotechnology company that develops therapies to improve the treatment of brain tumors…

Walgreens Boots Alliance expected to report mixed Q1 2025 results

For Walgreens Boots Alliance, Inc. (NASDAQ: WBA), 2024 was a challenging year as it lost market share to competitors and…

“Gelteq has been continuously evolving to expand applications and audiences”

Gelteq Limited (NASDAQ: GELS) is a healthcare company specializing in the development and manufacturing of edible gel products, with a…

Pfizer (PFE) reaffirms FY24 forecast; provides FY25 guidance

Pharmaceutical company Pfizer Inc. (NYSE: PFE) Tuesday reaffirmed its financial outlook for fiscal 2024 and provided guidance for fiscal 2025.…

Earnings Summary: A snapshot of CooperCompanies (COO) Q4 2024 results

Medical device maker CooperCompanies (NYSE: COO) has announced financial results for the fourth quarter of 2024, reporting an increase in…

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer…

Earnings Summary: Moderna swings to profit in Q3 on modest revenue growth

Biotechnology company Moderna, Inc. (NASDAQ: MRNA) Thursday reported net income for the third quarter of 2024, compared to a loss…